Discontinued — last reported Q4 '22
Zimmer Biomet Holdings EMEA — Goodwill Impairment remained flat by 0.0% to $72.45M in Q4 2022 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Any impairment loss is a negative signal, indicating that previous acquisitions in the region are underperforming or facing significant market headwinds.
This represents a non-cash charge taken when the carrying value of goodwill associated with the EMEA segment exceeds its...
A significant negative event for any company; peers typically avoid this unless there is a major structural shift in the regional market.
zbh_segment_emea_goodwill_impairment_loss| FY'22 | |
|---|---|
| Value | $289.80M |